Prior to marketing approval in Japan in September 2020, this expanded-access study was conducted to provide T-DXd to previously treated patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinomas. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.